Genomic Health, Inc. (NASDAQ:GHDX) – Investment analysts at William Blair reduced their FY2017 earnings per share (EPS) estimates for Genomic Health in a note issued to investors on Monday. William Blair analyst A. Murphy now forecasts that the medical research company will earn ($0.09) per share for the year, down from their previous forecast of $0.01. William Blair also issued estimates for Genomic Health’s FY2019 earnings at $0.65 EPS.

GHDX has been the subject of several other reports. Zacks Investment Research raised Genomic Health from a “sell” rating to a “hold” rating in a report on Friday, October 13th. ValuEngine cut Genomic Health from a “hold” rating to a “sell” rating in a report on Thursday, November 9th. Canaccord Genuity reaffirmed a “buy” rating and issued a $35.00 price objective on shares of Genomic Health in a report on Wednesday, September 27th. Jefferies Group LLC reaffirmed a “hold” rating and issued a $33.00 price objective on shares of Genomic Health in a report on Thursday, September 14th. Finally, Piper Jaffray Companies reaffirmed a “hold” rating and issued a $31.00 price objective on shares of Genomic Health in a report on Thursday, August 3rd. Two analysts have rated the stock with a sell rating, seven have given a hold rating and one has given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $32.00.

TRADEMARK VIOLATION WARNING: “Genomic Health, Inc. (GHDX) Expected to Earn FY2017 Earnings of ($0.09) Per Share” was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece can be read at https://www.americanbankingnews.com/2017/11/15/genomic-health-inc-ghdx-expected-to-earn-fy2017-earnings-of-0-09-per-share.html.

Genomic Health (NASDAQ GHDX) opened at $28.38 on Wednesday. Genomic Health has a fifty-two week low of $26.37 and a fifty-two week high of $34.02.

In related news, insider James J. Vaughn sold 1,379 shares of the business’s stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $32.51, for a total transaction of $44,831.29. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, COO G Bradley Cole sold 5,000 shares of the business’s stock in a transaction on Tuesday, November 7th. The stock was sold at an average price of $31.47, for a total value of $157,350.00. The disclosure for this sale can be found here. Insiders have sold a total of 21,379 shares of company stock valued at $676,131 in the last three months. 46.20% of the stock is owned by insiders.

A number of hedge funds have recently modified their holdings of GHDX. American International Group Inc. grew its position in Genomic Health by 7.1% during the 1st quarter. American International Group Inc. now owns 11,505 shares of the medical research company’s stock worth $362,000 after acquiring an additional 765 shares during the last quarter. TIAA CREF Investment Management LLC grew its position in Genomic Health by 5.6% during the 1st quarter. TIAA CREF Investment Management LLC now owns 71,233 shares of the medical research company’s stock worth $2,243,000 after acquiring an additional 3,808 shares during the last quarter. Legal & General Group Plc grew its position in Genomic Health by 48.7% during the 1st quarter. Legal & General Group Plc now owns 6,222 shares of the medical research company’s stock worth $196,000 after acquiring an additional 2,038 shares during the last quarter. Vanguard Group Inc. grew its position in Genomic Health by 8.8% during the 1st quarter. Vanguard Group Inc. now owns 1,564,170 shares of the medical research company’s stock worth $49,256,000 after acquiring an additional 126,807 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in Genomic Health by 7.0% during the 1st quarter. Geode Capital Management LLC now owns 205,838 shares of the medical research company’s stock worth $6,480,000 after acquiring an additional 13,549 shares during the last quarter. Institutional investors and hedge funds own 89.13% of the company’s stock.

Genomic Health Company Profile

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Earnings History and Estimates for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.